Business Context and Reporting Period
This Form 8-K is a current report filed by AspenBio Pharma, Inc. (not Riot Platforms, Inc.) on January 19, 2009. The filing discloses material corporate governance changes, specifically the appointment of new leadership and the entry into a material employment agreement.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on executive compensation and corporate appointments.
- Executive Compensation: Daryl J. Faulkner appointed as Executive Chairman with an annual salary of $250,000.
- Equity Grant: Faulkner granted stock options for 500,000 common shares (100,000 subject to forfeiture) under the 2002 Stock Incentive Plan.
- Option Terms: Vest annually in arrears over three years; expire in ten years; exercise price set at fair market value on January 26, 2009.
- Severance: Six months of salary and benefits upon termination (excluding death/disability); three months upon death or disability.
Material Changes Versus Prior Period
The filing details significant changes to the Board of Directors and executive leadership effective January 26, 2009:
- Board Expansion: The Board size was expanded to nine members to accommodate the new Executive Chairman position.
- New Appointment: Daryl J. Faulkner appointed to the Board as Executive Chairman.
- Title Change: Gregory Pusey's title changed to Vice Chairman.
- Committee Addition: John Landon added to the Compensation Committee.
Guidance, Outlook, and Other Events
The filing references two press releases issued on January 20, 2009, and a conference call on January 21, 2009:
- Leadership Update: Announcement of Daryl J. Faulkner's appointment.
- Clinical Study Results: Preliminary results of the AppyScore clinical study were reported (details of results not included in this text).
- Management Commentary: Faulkner brings over 25 years of experience in medical devices and diagnostics, including prior roles at Digene Corporation, Invitrogen, and Abbott Laboratories.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "disability" and forfeiture conditions.
- Review the AppyScore Clinical Study press release (Exhibit 99.2) for specific data points regarding the preliminary results.
- Confirm the fair market value of the stock on January 26, 2009, to determine the exercise price of the 500,000 options.
- Check subsequent filings for the outcome of the 2009 Annual Meeting of Shareholders regarding Faulkner's election.